About
June Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, where she oversaw R&D, corporate governance, partnering, and commercial strategy during a tenure that culminated in the company's acquisition by Actavis for approximately $1.2 billion in 2015. She subsequently held the role of Chief Medical Officer at RedHill Biopharma from 2019 to 2024 and currently serves as Co-Founder and Executive Board Chair of 82VS Newco, a venture portfolio company affiliated with Alloy Therapeutics, while maintaining board positions at multiple public and private biopharmaceutical companies and providing advisory services in translational medicine, clinical development, and commercial strategy across multiple therapeutic areas.
Experience
- 82VS Newco (venture portfolio company for 82VS, affiliated with Alloy therapeutics)Co-Founder, Executive Board Chaircurrent2025 — present
- Founder, Exec. Chair, Portfolio company w/82VS (affiliated with Alloy Therapeutics), Waltham, MAExecutive Venture Partnercurrent2024 — present
- BiopharmaBoard Member, Consultant, Chief Medical Officer, C level biotech exec.current2015 — presentRaleigh-Durham, North Carolina Area
- Hatteras Venture PartnersExecutive-in-Residence, consultant2014 — 2015Raleigh-Durham, North Carolina Area
- Furiex Pharmaceuticals (FURX: Nasdaq); acquired by Actavis for $1.2BPresident, Chief Medical Officer and Board Director2010 — 2014Morrisville, NC
- GlaxoSmithKlineVice President, Clinical Safety-Pharmacovigilance at GSK2005 — 2010
- GlaxoSmithKlineScientific Licensing, Business Development2008 — 2009
- GlaxoSmithKlineMedical Director1997 — 2008
- Duke University Medical CenterAsst. Professor Internal Medicine & Pharmacology1993 — 1996
Skills & more
Start-up VenturesTranslational MedicineBoard of Directors1Venture PhilanthropyExecutive Leadership1Executive Management7Drug Development40Pharmaceutical Industry44Clinical Development33Biotechnology32Business Strategy7Strategy11
+12 more
MedicineDrug DiscoveryPharmacovigilanceDue DiligenceClinical TrialsInfectious DiseasesR&DOncologycommercial strategyBiopharmaceuticalsVenture CapitalResearch and Development (R&D)From June's professional profile.
Colleagues at 82VS
Andrei Ramirez-Valdez
Venture Associate at 82VS
Andrew Peterson
Founder / EIR at 82VS
Arthur Suckow
Investor at 82VS
Caitlin Tolman
Chief Operating Officer at 82VS
Carlos Loya
Venture Partner & Founder at 82VS
Colby Jordan
Vice President, Capital Formation at 82VS
Dongxing Zha
Founder / EIR at 82VS
Errik Anderson
Board Director at Basecamp Fund
Frequently asked questions
- Who is June Almenoff?
- June Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, where she oversaw R&D, corporate governance, partnering, and commercial strategy during a tenure that culminated in the company's acquisition by Actavis for approximately $1.2 billion in 2015. She subsequently held the role of Chief Medical Officer at RedHill Biopharma from 2019 to 2024 and currently serves as Co-Founder and Executive Board Chair of 82VS Newco, a venture portfolio company affiliated with Alloy Therapeutics, while maintaining board positions at multiple public and private biopharmaceutical companies and providing advisory services in translational medicine, clinical development, and commercial strategy across multiple therapeutic areas.
- Where does June Almenoff work?
- June Almenoff is Advisor at 82VS.
- Where did June Almenoff go to school?
- June Almenoff studied at Stanford University School of Medicine (Residency, Postdoc); Mt. Sinai School of Medicine (now Icahn School of Medicine) (MD, PhD (dual degree program)); Smith College (BA, cum laude).
Same school
Also attended Stanford University School of Medicine83
Jeffrey FinerVenture Partner at Third Rock VenturesRebecca MancusiInvestor at Third Rock VenturesSebastian CaliriInvestment Team at 8VCAlex MorganInvestor at Khosla VenturesLauren PopovAssociate at Westlake Village BioPartnersClare OzawaManaging Director at Versant Ventures
+ 77 more
Also attended Smith College26
Natasha SharmaInvestor at True VenturesNigel CarrDirector at Acario InnovationSu FuAffiliate at ARCH Venture PartnersLeah PalmerManaging Director and General Counsel at Spectrum EquitySun AltbachSenior Scientific Advisor at BOLD LongevityLaurel ToubyManaging Partner at Supernode Ventures
+ 20 more
Shared employers
Also worked at Hatteras Venture Partners17
Fred GoldwaterDigital Health Advisor at Excelerate Health VenturesJeff TerrellPartner at Arboretum VenturesKenneth LeeJr., General Partner at Hatteras Venture PartnersDouglas ReedGeneral Partner at Hatteras Venture PartnersClay ThorpGeneral Partner at Hatteras Venture PartnersJohn CrumplerGeneral Partner at Hatteras Venture Partners
+ 11 more
Also worked at GlaxoSmithKline116
Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Victoria TaylorInvestor at MedicxiErin MooreInvestor at Third Rock VenturesJeb KeiperInvestor at Third Rock VenturesJane SuhPrincipal on the AlleyCorp Healthcare teamCarol SuhPartner at ARCH Venture Partners
+ 110 more
